The Primary Aldosteronism Screening to Treatment Pathway (PASTP) is part of a quality improvement and research initiative designed to understand and reduce barriers to screening and treatment for primary aldosteronism.
Primary aldosteronism is a very common but under-diagnosed and under-treated cause of hypertension, cardiovascular disease and chronic kidney disease.
Here we provide our streamlined screening to treatment algorithm which is based on the 2025 Endocrine Society Clinical Practice Guideline for Primary Aldosteronism.
Contact Us
For more information please email philip.knapp@bmc.org.
Algorithm
